Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An international, 6,000-patient Phase IIIb ASSENT 3 study will evaluate TNKase with heparin, Lovenox enoxaparin low molecular weight heparin from Aventis S.A.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury